Sanofi is going to “look very deeply” at its late-stage pipeline as part of a portfolio prioritization initiative, though new CEO Belén Garijo didn’t commit to shelving a specific number of assets.

Original title: “Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions”

In this episode of Denatured presented by Arvinas, Jennifer Smith-Parker speaks to Arvinas President and CEO Randy Teel about the strategic discipline and leadership required to successfully refocus a company on an early-stage pipeline after a lead asset is outlicensed, discontinued or otherwise falls away.

Original title: “Life after the lead asset: Advancing an early-stage pipeline”

So far in 2026, over 50 biopharmas have cut or plan to cut their workforces. If they didn’t take a careful, thoughtful approach to telling people they were being laid off, they likely left a negative impression on employees, based on stories shared with BioSpace.

Original title: “Not-so-special delivery: When biopharmas fumble layoff news”

With so many unknowns, Biogen is carefully eyeing its next-gen Alzheimer’s treatment diranersen as a high-risk, high-reward project with the potential for a major payout around 2030.

Original title: “Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store”

Though positive, mid-stage study results erased about two-thirds of the biotech's market value this week. But Christopher Kroeger sees MapLight's drug as competitive based on the "totality of data."

Original title: “MapLight CEO on what investors missed in the biotech’s schizophrenia data”

Reverse mergers and acquisitions remain a viable path to the public market for venture-backed biotechs, with Caldera Therapeutics and Vidya Therapeutics announcing separate deals on Wednesday to advance immunology and inflammation assets.

Original title: “Private biotechs Caldera and Vidya raise $478M collectively in reverse go-public mergers”

The startups are part of a surge of young companies equipped with advanced drug prospects and quickly pivoting to the public markets.

Original title: “Caldera, Vidya add to recent flurry of biotech mergers”

The deal adds to a growing streak of partnerships involving new types of T cell engagers and gives Vertex another chance to broaden a business still reliant on cystic fibrosis medicines.

Original title: “AbCellera, Vertex partner on next-gen T-cell engagers”

Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.

Original title: “Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push”

Replimune shares plummeted 40% on concerns FDA scientists are still skeptical of its melanoma drug. Elsewhere, investors had a muted reaction to a first-of-its-kind study result.

Original title: “FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data”

ElevateBio will be the primary source of Kyverna’s autologous CAR-T cell therapy for anticipated U.S. and global launches in autoimmune indications.

Original title: “Kyverna taps ElevateBio to secure commercial supply of autoimmune CAR-T therapy”

Business stage is just one factor in whether biopharmas want job candidates to have oncology experience for oncology roles. Two recruiters explain when oncology expertise matters most, the mistakes job seekers make and how to make a good impression.

Original title: “Do you need oncology experience to land an oncology job?”